Photoselective vaporization of the prostate using the 120-W lithium triborate laser in enlarged prostates (>120 cc)

BJU Int. 2011 Sep;108(6):860-3. doi: 10.1111/j.1464-410X.2010.09855.x. Epub 2010 Nov 24.

Abstract

OBJECTIVE • To evaluate experience with high power LBO laser for large prostates

Patients and methods: • Prospective database of 288 men treated with PVP from November 2006-2009 • 33 men identified to have transrectal ultrasound measured prostate size >120 cc • All but 9 men not in urinary retention or on anticoagulant medications • Average ASA Score 2.25 (range 1-4) with 11 having an ASA Score of 3 or more

Results: • Mean operating time and laser time 109 and 86 minutes respectively • IPSS, QoL and Qmax changes from baseline to 3 months for those not in retention were 24 to 8.6, 5.0 to 1.8 and 7.5 mL/s to 19.6 mL/s respectively • Post void residual in these men fell from a mean of 235 mL to 88 mL • Average fall in PSA was 38% for 22 men with paired PSA data • Post operative urinary retention in 4 men resolved. 2 late onset clot urinary retention

Conclusion: • Early results demonstrate PVP to be safe and efficacious on early follow up in a high risk group of patients with significantly enlarged prostates, anticoagulation and urinary retention.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Feasibility Studies
  • Humans
  • Laser Therapy / instrumentation*
  • Laser Therapy / methods
  • Length of Stay
  • Male
  • Middle Aged
  • Organ Size
  • Prospective Studies
  • Prostate-Specific Antigen / metabolism
  • Prostatic Hyperplasia / blood
  • Prostatic Hyperplasia / pathology
  • Prostatic Hyperplasia / surgery*
  • Prostatism / blood
  • Prostatism / pathology
  • Prostatism / surgery
  • Quality of Life
  • Treatment Outcome
  • Urinary Catheterization / methods
  • Urinary Retention / blood
  • Urinary Retention / pathology
  • Urinary Retention / surgery

Substances

  • Prostate-Specific Antigen